GNPX Quote, Financials, Valuation and Earnings

IN8bio has a net margin of -- compared to Genprex's net margin of --. Genprex's return on equity of -- beat IN8bio's return on equity of --.

Genprex has a consensus price target of --, signalling upside risk potential of 724.18%. On the other hand IN8bio has an analysts' consensus of -- which suggests that it could grow by 1809.16%. Given that IN8bio has higher upside potential than Genprex, analysts believe IN8bio is more attractive than Genprex.

Genprex has a beta of -1.377, which suggesting that the stock is 237.675% less volatile than S&P 500. In comparison IN8bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genprex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IN8bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex pays -- of its earnings as a dividend. IN8bio pays out -- of its earnings as a dividend.

Genprex quarterly revenues are --, which are smaller than IN8bio quarterly revenues of --. Genprex's net income of -$4.3M is higher than IN8bio's net income of -$7.1M. Notably, Genprex's price-to-earnings ratio is -- while IN8bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex is -- versus -- for IN8bio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Genprex's net margin of -49.65%. Genprex's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Genprex has a consensus price target of --, signalling upside risk potential of 724.18%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that Genprex has higher upside potential than NovaBay Pharmaceuticals, analysts believe Genprex is more attractive than NovaBay Pharmaceuticals.

Genprex has a beta of -1.377, which suggesting that the stock is 237.675% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Genprex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Genprex quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Genprex's net income of -$4.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Genprex's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Genprex's net margin of -2357.27%. Genprex's return on equity of -- beat Palatin Technologies's return on equity of --.

Genprex has a consensus price target of --, signalling upside risk potential of 724.18%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Genprex, analysts believe Palatin Technologies is more attractive than Genprex.

Genprex has a beta of -1.377, which suggesting that the stock is 237.675% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Genprex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Genprex quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Genprex's net income of -$4.3M is higher than Palatin Technologies's net income of -$7.8M. Notably, Genprex's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics has a net margin of -- compared to Genprex's net margin of --. Genprex's return on equity of -- beat Sensei Biotherapeutics's return on equity of --.

Genprex has a consensus price target of --, signalling upside risk potential of 724.18%. On the other hand Sensei Biotherapeutics has an analysts' consensus of -- which suggests that it could grow by 816.87%. Given that Sensei Biotherapeutics has higher upside potential than Genprex, analysts believe Sensei Biotherapeutics is more attractive than Genprex.

Genprex has a beta of -1.377, which suggesting that the stock is 237.675% less volatile than S&P 500. In comparison Sensei Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genprex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex pays -- of its earnings as a dividend. Sensei Biotherapeutics pays out -- of its earnings as a dividend.

Genprex quarterly revenues are --, which are smaller than Sensei Biotherapeutics quarterly revenues of --. Genprex's net income of -$4.3M is higher than Sensei Biotherapeutics's net income of -$7.3M. Notably, Genprex's price-to-earnings ratio is -- while Sensei Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex is -- versus -- for Sensei Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.